Literature DB >> 26297177

IL-20 in rheumatoid arthritis.

Yu-Hsiang Hsu1, Ming-Shi Chang2.   

Abstract

Rheumatoid arthritis, a systemic autoimmune disease, causes chronic joint inflammation and bone destruction. Interleukin (IL)-20's association with this disease, and its expression and regulation has been extensively studied since 2006. Anti-IL-20 antibody has paved the way to clinical trials aimed at blocking the pathogenic actions of IL-20 in rheumatoid arthritis. This review focuses on current knowledge of IL-20's involvement in the pathogenesis of rheumatoid arthritis.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26297177     DOI： 10.1016/j.drudis.2015.08.002

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN： 1359-6446            Impact factor:   7.851


  8 in total

1.  Expression of IL-20 Receptor Subunit β Is Linked to EAE Neuropathology and CNS Neuroinflammation.

Authors:  Jacquelyn R Dayton; Yinyu Yuan; Lisa P Pacumio; Bryce G Dorflinger; Samantha C Yoo; Mariah J Olson; Sara I Hernández-Suárez; Moira M McMahon; Lillian Cruz-Orengo
Journal:  Front Cell Neurosci       Date:  2021-09-07       Impact factor: 6.147

2.  Interleukin-20 is involved in dry eye disease and is a potential therapeutic target.

Authors:  Hsiao-Hsuan Wang; Wei-Yu Chen; Yi-Hsun Huang; Sheng-Min Hsu; Yeou-Ping Tsao; Yu-Hsiang Hsu; Ming-Shi Chang
Journal:  J Biomed Sci       Date:  2022-06-09       Impact factor: 12.771

3.  Anti-IL-20 monoclonal antibody inhibited inflammation and protected against cartilage destruction in murine models of osteoarthritis.

Authors:  Yu-Hsiang Hsu; Ya-Yu Yang; Man-Hsiang Huwang; Yun-Han Weng; I-Ming Jou; Po-Tin Wu; Tain-Yu Lin; Li-Wha Wu; Ming-Shi Chang
Journal:  PLoS One       Date:  2017-04-20       Impact factor: 3.240

4.  Analysis of interleukin-20 receptor complexes in trabecular meshwork cells and effects of cytokine signaling in anterior segment perfusion culture.

Authors:  Kate E Keller; Yong-Feng Yang; Ying Ying Sun; Mark R Walter; Mary K Wirtz
Journal:  Mol Vis       Date:  2019-04-27       Impact factor: 2.367

5.  Interleukin-18, interleukin-20, and matrix metalloproteinases (MMP-1, MMP-3) as markers of psoriatic arthritis disease severity and their correlations with biomarkers of inflammation and turnover of joint cartilage.

Authors:  Michał Waszczykowski; Igor Bednarski; Joanna Narbutt; Elżbieta Waszczykowska; Aleksandra Lesiak; Jarosław Fabiś
Journal:  Postepy Dermatol Alergol       Date:  2020-05-04       Impact factor: 1.837

6.  Serum and synovial fluid concentrations of interleukin-18 and interleukin-20 in patients with osteoarthritis of the knee and their correlation with other markers of inflammation and turnover of joint cartilage.

Authors:  Michał Waszczykowski; Anna Fabiś-Strobin; Igor Bednarski; Joanna Narbutt; Jarosław Fabiś
Journal:  Arch Med Sci       Date:  2020-07-03       Impact factor: 3.318

Review 7.  IL-20 bone diseases involvement and therapeutic target potential.

Authors:  Hsiao-Hsuan Wang; Yu-Hsiang Hsu; Ming-Shi Chang
Journal:  J Biomed Sci       Date:  2018-04-24       Impact factor: 8.410

8.  I-Kappa-B-Zeta Regulates Interleukin-17A/Tumor Necrosis Factor-Alpha Mediated Synergistic Induction of Interleukin-19 and Interleukin-20 in Humane Keratinocytes.

Authors:  Trine Bertelsen; Lars Iversen; Claus Johansen
Journal:  Ann Dermatol       Date:  2021-03-08       Impact factor: 1.444
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.